pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-9-1 |
Genomic Coordinates | chr1: 156420341 - 156420429 |
Synonyms | MIRN9-1, hsa-mir-9-1, miRNA9-1, MIR9-1 |
Description | Homo sapiens miR-9-1 stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
pre-miRNA | hsa-mir-9-2 |
Genomic Coordinates | chr5: 88666853 - 88666939 |
Synonyms | MIRN9-2, hsa-mir-9-2, miRNA9-2, MIR9-2 |
Description | Homo sapiens miR-9-2 stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
pre-miRNA | hsa-mir-9-3 |
Genomic Coordinates | chr15: 89368017 - 89368106 |
Synonyms | MIRN9-3, hsa-mir-9-3, miRNA9-3, MIR9-3 |
Description | Homo sapiens miR-9-3 stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-9-3p | ||||||||||||||||||||||||||||||||||||||||||
Sequence | 55| AUAAAGCUAGAUAACCGAAAGU |76 | ||||||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
DRVs in miRNA |
|
||||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | RCOR1 | ||||||||||||||||||||
Synonyms | COREST, RCOR | ||||||||||||||||||||
Description | REST corepressor 1 | ||||||||||||||||||||
Transcript | NM_015156 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on RCOR1 | |||||||||||||||||||||
3'UTR of RCOR1 (miRNA target sites are highlighted) |
>RCOR1|NM_015156|3'UTR 1 GAAACTGGTGGCTTTGAACACTTGGTGTGGACTACTGTGTTATCCGGGATATCAGGTATTATGAGACATCACCTAGCCAT 81 CTGCATCACATCTCTCTGGACAAGCAGCTATTACCAAAAAAGGCATATACTTCCAGTCCTGTGCTCCATCTGCCTTAATT 161 CTTTGCTCGTTCCTCCATGTTGGCGCCACTTCCCAGAGAGCTCCACTGCATCTCACACTCTGCCCACGTGCTGGGGAAGT 241 CTCACGGCCTGCACATCTCTTGTGACTCTGGGAACCGCCTCTCCCGCCGGAGCCCCCGAGCCCCACCAATGGCAGCTCTT 321 CCCAGTCAGCAGCTTCAGAGCAGGCAGTCTCCTTGGAAGGCCCGACTCTGTTCCTGCATGGCCTGCAGTTTCTACTTTGT 401 GCATAGAGTCATTTTCAGAGTCACCGCGACCCTGTTGGCCTTCTAGAAAGTTTCTTTTGTTCTTTTCTGAGACAACCACC 481 TAAGTGATAATACGCTTTTTTGGAAACTAATATATATTGCCAGACTGCATCATAACCTTTATCATGCCAAGCATCCTGAT 561 GCAACTCACATTTCCCTAAACATGGGGTACAGTTATGATTTATAAATTGAGTTGGCTTAAATCTCCCTCTTCTCCCTTCC 641 CAAGTGTTACAAAGATCATTTACTGCAACTGTCGTTGGACACTGTAGCTTAAAGGGAACGTGGACCTCAATGCTTTCTGC 721 CTTCAACTTTTCAGCATTGTGACCCCAGGGTGGTTGCCACCCCATCTTTTCCTGACCCCCCCCACCCCCCCACCTCCAAG 801 AGGTTCGGCCCACATCACTGTACCTGGTGCTTGTAAATTTGGAATTGGTGCCTTCTCCTTTTGGCAACCATGGTTATCAA 881 TCCTTTTTCTGTTTTAGTGTCTTATTTCTTCTTTCAAGTTATTTGCTAGCCAAAGATGACATCACTGAGATTAGGAGACA 961 GGGGAGAGCTTGCTGCAGATTCTGACAGTGCAGATTTTAAATGTCAGGATATTAGAATAGCTGGCGCTGGTTTATGAAAG 1041 CTGCGCGTTGTTCCGCGTTCTCTCGGTGTGCCTGGCCTTTTATGTGGCACTCTGTATGTCAGTTTGTGTCCTTCATGTGC 1121 TGATGTGATTACACAAACACCATGCACTCTCTTTTCATATCAGAGTACAGGACAGAGAAGTGATCAATGTATTGGTCTAG 1201 TGAGACTGAGATGAAAAGAAATAACCTACAGAGTGGTCTGTAATGCCTTTTGGTTGGACTGGGAACAAGTAAAAATTTCT 1281 AATAAACATTTTGAGACTTCCAGAATCACTTTTGTTATCTTATCAGACCATGGGCCTGCTGAGGGTTGAGCAGACAGCCT 1361 GCATTCTAACATACCCTGTTCCCACCCCACGGCCATTCAGACTGCACTCAATACGCTGAAGTCGCTTTTGTTGTTGTTGT 1441 TGTTGTTTGCATCATTTGGATTTTTTTCCTGCTTTCAATACCAAAAAAATGCAGATGCTTTAAGGCCTAAACAGAATTCT 1521 GAAGAATTTAAAATATGCAATTAAAGTTTGATATGTTTTGTCTCCCAAGCACCTTGTTTTTTGTTGTTGTTGTTGTTGTT 1601 GAAGTCAGCTGATTTTCTCTTTAGAAAGAGGGTCAGCTAGAAACCTAGGTTTTTTGGAATTGTAAATTTTTTTTTAGTAT 1681 AGTCTGGAGAGAAAGGTCATTCAAAAGGAAAGTACAATGGGACTTGCTGCCCTTCATCATCTCGTTCCCGTGCCAGGTGT 1761 GTGTTGGTCACGTAAAAGCCTGGGAAGCATCAGAGGAGTCCCGGATTGCTGCTGCTACCTGGAGACAGGGTTAGCAAAAT 1841 AACACTAGTGATGAGGGAGAGGCTTCTTTTCACCATAAGCCTGCTGTGTACACCGAGGGCGGCAGGAGAAGCATGGGAAG 1921 GAGTCAGCCTAAGTTTGCACATTGCATAAAGGGTACACTAAGGTATGAGCTGAAGCTTTAGGTTCTCCGTGCTTCCCTCA 2001 AGACCTCCTTCTTGCTAACAGAAGCAGTAGGCAATTGCTGCAGTGCGTTTCTCACCCTGCCAATAGGTCTGTCTGTATCT 2081 CTGTTAAGGAAAATAGCCTGGTCCCTCCTGGCAGTGCTTGGAAGCTTGATGCTAATTTTTATATAGCGTGGCAAACTGAC 2161 CAGCAGTGCCAGGCCTTGATCTGTATTCTGCACTATCCCTTTACTTGGTTCCTGGCACTGAATGGTCTCCAGCCCTGAAG 2241 AATCACGTGTGATCACAGCAGCTGACCTGGGCTTTCTCCCCGAGAGGAAGGGGCATGTCATTTTTATTTGACAGAGGGAA 2321 AATGGGAGCTGTCCTTGACTGCCTTTGTTGTGCTTTCCCGCGTAAGATAGCACTGTGTTTTAAACTGTTGCATTACACTG 2401 TCTTTGCAATGATGTAAATGTAAGAAATCACTTAGCTTTAAAAGCGCAGTGGTTTGATCTTATTTATATGAAGACTTTTT 2481 AACATATCAAGAATTAGGTGCATTGGCAGGTAGGGTTTGGGGTGTGATAACTGCTTCAGATGGAATGTTCACTTAAGCTT 2561 TGTCTTCTTAAAAATTATCAATGTGAATGTCATAATTATATATATTTTTGTGGAAAATTTTCTCCTAAGTATAAGTTATT 2641 GTGCAAAATATAGTGTCATTGATGCAAATAATAGTTTAACTTTTAGTTTAGAACTCCTAAAAGATATAAATTGTATTGCA 2721 TATGCATTAAAAGTTTGTTTTATTTAATTTTATGTAGATGTGTGAAGTGTTAGGTAAAATTTTTTTCACTTATCCATTTA 2801 AACACCTTGTTACTTGAATATTGTGTTGACTGGTCTGCAACAGTGATCCATTCTGTAATATAGCTCTTTTAACTGGGAAG 2881 GAACCACACCCCAGTTGTGCCGATTACATTAGTGTTGGCACACAGTCGGGTGCTAGTGTAACACAAATGCCGCGTTGTCT 2961 GGGTGTACAGTGTTTGTGGAGACGCCACTTCCTCAAAATGGTTTTTGATTGTTTTTAACCTATAAGACGTTCTGATGCTC 3041 ACAAACCTCTATTCAACACACAAAACAAACATGAAAAGGTAGTTAGTTGGGTTGTAACAGCTTACTGGGGTGGACTCATA 3121 AAACAGTGGCTTTCTGTTCATCTAAAGTTTCCTCAGATACCACAGACCACTGTTAAGTGTGCTCATTGTCACTTTAAATT 3201 TCAACGATACCCTATTTTTGTCATTCTAAATATCAGATGTACTATTGGTATAATTGCACACCAAAAATAAGCCAAACAGT 3281 GCATTACGCTAACTGGATCCCTGCTTTTATGTGAGCTAAGGAAAGATGGAGCCAACTCCAACGAGGGCCTCTTTTTCTCT 3361 CTTGTCTAGCCTGTTTCTAAACCGAATGATCCAGGATTCAAGCTTCTATTGTCAAGTGAAACTTTCCTCAGATGGACTCC 3441 AGGTAGCCAGGTCACCTAAACCTAGTGGTCCTGTGCGATGCTCTTTCTGCCAGTCCCTGAATCTCTGCAGCTTCTCTTAC 3521 CTGTCTTACCTGTAGTAAAGCACAATTGCAGTGGCGTCGCATTCAGAAGAAGGGAAGGTCAGCAGAGGCTATGCATGTTG 3601 TGTGATGATGAGTGTTTACAGCCACCTTCTCCTAAAACGAAATTTATACCGGGGTGGATAGTATTCCATTAGGTAGACTT 3681 ATCGACTTTGCTAAGTGCTTTTTAGACAGCTTAAAAAATTTTCAAGATTTTAAAAGATGTATAAGGTTAAGTTTGCAAAT 3761 ATAATGGAAATGCTGTATATCTTTTGAAGTGATGAAATCCACGTTGGAATTTTAAAGAAAATATGTTGTAATAATGCTGT 3841 TGTAAGTAATATTTTAATGTCTCTTTGCCTGTTTTCTATTTCAGCACATTCATTGTGGTGAATGTTCATAGCATTATAAC 3921 TGCTTAGCCATTGAATGATAACATTTGTTAGTGGAAATTGGAAAATTTATTTGTGAAATTCTGCAGAATTCATTTTTCTA 4001 TTTCCAATATTTGCTGAGGTTAAATAAAAATTTTCAAGCCATTGATGTAATAAAATATGAAATGAAAGCAAAAAAAAAAA 4081 AAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 , NT2 |
Disease | ken; |
Location of target site | 3'UTR |
Original Description (Extracted from the article) |
...
"miR-9* targets the 3'UTR of CoREST.//Cotransfection of the CoREST 3'UTR reporter plasmid and 5 or 15 nM pre-miR-9* reduced reporter expression compared with controls (F(2
... - Packer AN; Xing Y; Harper SQ; Jones L; Davidson BL, 2008, The Journal of neuroscience : the official journal of the Society for Neuroscience. |
Article |
- Packer AN; Xing Y; Harper SQ; Jones L; Davidson BL - The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008
The transcription factor REST silences neuronal gene expression in non-neuronal cells. In neurons, the protein is sequestered in the cytoplasm in part through binding to huntingtin. Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding. Consequently, REST translocates to the nucleus, occupies RE1 repressor sequences and decreases neuronal gene expression. In this work, we found that levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls. Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST. These data provide evidence for a double negative feedback loop between the REST silencing complex and the miRNAs it regulates.
LinkOut: [PMID: 19118166]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Article |
- Genovesi LA; Carter KW; Gottardo NG; Giles et al. - PloS one, 2011
Medulloblastoma (MB) is the most common malignant brain tumor in children and a leading cause of cancer-related mortality and morbidity. Several molecular sub-types of MB have been identified, suggesting they may arise from distinct cells of origin. Data from animal models indicate that some MB sub-types arise from multipotent cerebellar neural stem cells (NSCs). Hence, microRNA (miRNA) expression profiles of primary MB samples were compared to CD133+ NSCs, aiming to identify deregulated miRNAs involved in MB pathogenesis. Expression profiling of 662 miRNAs in primary MB specimens, MB cell lines, and human CD133+ NSCs and CD133- neural progenitor cells was performed by qRT-PCR. Clustering analysis identified two distinct sub-types of MB primary specimens, reminiscent of sub-types obtained from their mRNA profiles. 21 significantly up-regulated and 12 significantly down-regulated miRNAs were identified in MB primary specimens relative to CD133+ NSCs (p<0.01). The majority of up-regulated miRNAs mapped to chromosomal regions 14q32 and 17q. Integration of the predicted targets of deregulated miRNAs with mRNA expression data from the same specimens revealed enrichment of pathways regulating neuronal migration, nervous system development and cell proliferation. Transient over-expression of a down-regulated miRNA, miR-935, resulted in significant down-regulation of three of the seven predicted miR-935 target genes at the mRNA level in a MB cell line, confirming the validity of this approach. This study represents the first integrated analysis of MB miRNA and mRNA expression profiles and is the first to compare MB miRNA expression profiles to those of CD133+ NSCs. We identified several differentially expressed miRNAs that potentially target networks of genes and signaling pathways that may be involved in the transformation of normal NSCs to brain tumor stem cells. Based on this integrative approach, our data provide an important platform for future investigations aimed at characterizing the role of specific miRNAs in MB pathogenesis.
LinkOut: [PMID: 21931624]
|
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
86 hsa-miR-9-3p Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT003911 | RCOR1 | REST corepressor 1 | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT035520 | ITGB1 | integrin subunit beta 1 | ![]() |
1 | 1 | |||||||
MIRT054491 | GNAI1 | G protein subunit alpha i1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT063596 | FBXO28 | F-box protein 28 | ![]() |
![]() |
2 | 4 | ||||||
MIRT065157 | SLC38A2 | solute carrier family 38 member 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT296352 | PARD6B | par-6 family cell polarity regulator beta | ![]() |
![]() |
2 | 2 | ||||||
MIRT362144 | MTRNR2L6 | MT-RNR2-like 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT386279 | ITPRIPL2 | inositol 1,4,5-trisphosphate receptor interacting protein like 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT391503 | C5ORF51 | chromosome 5 open reading frame 51 | ![]() |
![]() |
2 | 2 | ||||||
MIRT441454 | PKD2L2 | polycystin 2 like 2, transient receptor potential cation channel | ![]() |
![]() |
2 | 2 | ||||||
MIRT441494 | TSC22D1 | TSC22 domain family member 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT441609 | ATP13A4 | ATPase 13A4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT441971 | RNF41 | ring finger protein 41 | ![]() |
![]() |
2 | 2 | ||||||
MIRT442615 | PPP3R1 | protein phosphatase 3 regulatory subunit B, alpha | ![]() |
![]() |
2 | 2 | ||||||
MIRT442676 | G2E3 | G2/M-phase specific E3 ubiquitin protein ligase | ![]() |
![]() |
2 | 2 | ||||||
MIRT442779 | INO80C | INO80 complex subunit C | ![]() |
![]() |
2 | 2 | ||||||
MIRT443185 | NHS | NHS actin remodeling regulator | ![]() |
![]() |
2 | 4 | ||||||
MIRT443519 | P2RX7 | purinergic receptor P2X 7 | ![]() |
![]() |
2 | 2 | ||||||
MIRT444526 | EIF2A | eukaryotic translation initiation factor 2A | ![]() |
![]() |
2 | 2 | ||||||
MIRT448920 | CKS1B | CDC28 protein kinase regulatory subunit 1B | ![]() |
![]() |
2 | 2 | ||||||
MIRT449104 | CREBRF | CREB3 regulatory factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT449333 | ACTBL2 | actin, beta like 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT456857 | ZNF460 | zinc finger protein 460 | ![]() |
![]() |
2 | 10 | ||||||
MIRT463797 | XPOT | exportin for tRNA | ![]() |
![]() |
2 | 2 | ||||||
MIRT469378 | REST | RE1 silencing transcription factor | ![]() |
![]() |
2 | 10 | ||||||
MIRT475190 | IMPDH1P11 | inosine monophosphate dehydrogenase 1 pseudogene 11 | ![]() |
![]() |
2 | 6 | ||||||
MIRT475942 | GXYLT1 | glucoside xylosyltransferase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT476714 | FRK | fyn related Src family tyrosine kinase | ![]() |
![]() |
2 | 4 | ||||||
MIRT493522 | IGF2 | insulin like growth factor 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT496868 | ASB7 | ankyrin repeat and SOCS box containing 7 | ![]() |
![]() |
2 | 2 | ||||||
MIRT498069 | SLC25A12 | solute carrier family 25 member 12 | ![]() |
![]() |
2 | 2 | ||||||
MIRT498303 | SDHC | succinate dehydrogenase complex subunit C | ![]() |
![]() |
2 | 2 | ||||||
MIRT502378 | GCC2 | GRIP and coiled-coil domain containing 2 | ![]() |
![]() |
2 | 6 | ||||||
MIRT503010 | CAPZA1 | capping actin protein of muscle Z-line alpha subunit 1 | ![]() |
![]() |
2 | 8 | ||||||
MIRT503917 | FBXL13 | F-box and leucine rich repeat protein 13 | ![]() |
![]() |
2 | 4 | ||||||
MIRT505283 | TTC9 | tetratricopeptide repeat domain 9 | ![]() |
![]() |
2 | 4 | ||||||
MIRT505294 | TPD52 | tumor protein D52 | ![]() |
![]() |
2 | 2 | ||||||
MIRT507086 | GPR180 | G protein-coupled receptor 180 | ![]() |
![]() |
2 | 4 | ||||||
MIRT511287 | KLHL15 | kelch like family member 15 | ![]() |
![]() |
2 | 4 | ||||||
MIRT511713 | HIST1H2BG | histone cluster 1 H2B family member g | ![]() |
![]() |
2 | 4 | ||||||
MIRT511956 | ELOVL5 | ELOVL fatty acid elongase 5 | ![]() |
![]() |
2 | 6 | ||||||
MIRT517723 | PAGR1 | PAXIP1 associated glutamate rich protein 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT521061 | SLC25A32 | solute carrier family 25 member 32 | ![]() |
![]() |
2 | 6 | ||||||
MIRT528079 | NOL9 | nucleolar protein 9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT530725 | C20orf196 | chromosome 20 open reading frame 196 | ![]() |
![]() |
2 | 2 | ||||||
MIRT532883 | ZNF451 | zinc finger protein 451 | ![]() |
![]() |
2 | 2 | ||||||
MIRT532962 | ZNF148 | zinc finger protein 148 | ![]() |
![]() |
2 | 2 | ||||||
MIRT535277 | PHOX2B | paired like homeobox 2b | ![]() |
![]() |
2 | 2 | ||||||
MIRT541046 | SLC25A36 | solute carrier family 25 member 36 | ![]() |
![]() |
2 | 2 | ||||||
MIRT542599 | YOD1 | YOD1 deubiquitinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT547395 | MKX | mohawk homeobox | ![]() |
![]() |
2 | 2 | ||||||
MIRT554615 | RPS6KA3 | ribosomal protein S6 kinase A3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT557439 | GTPBP2 | GTP binding protein 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT557769 | FRS2 | fibroblast growth factor receptor substrate 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT557835 | FNDC3B | fibronectin type III domain containing 3B | ![]() |
![]() |
2 | 2 | ||||||
MIRT559249 | BBX | BBX, HMG-box containing | ![]() |
![]() |
2 | 4 | ||||||
MIRT561033 | ASB6 | ankyrin repeat and SOCS box containing 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT562080 | KLHL11 | kelch like family member 11 | ![]() |
![]() |
2 | 2 | ||||||
MIRT562292 | GLO1 | glyoxalase I | ![]() |
![]() |
2 | 2 | ||||||
MIRT562987 | KIAA0408 | KIAA0408 | ![]() |
![]() |
2 | 2 | ||||||
MIRT565464 | SRSF6 | serine and arginine rich splicing factor 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT567908 | CRK | CRK proto-oncogene, adaptor protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT623676 | HOXD4 | homeobox D4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT630595 | C2CD2 | C2 calcium dependent domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT642471 | C16orf58 | chromosome 16 open reading frame 58 | ![]() |
![]() |
2 | 2 | ||||||
MIRT644846 | PGM2 | phosphoglucomutase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT650397 | ORMDL2 | ORMDL sphingolipid biosynthesis regulator 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT651686 | VPS13D | vacuolar protein sorting 13 homolog D | ![]() |
![]() |
2 | 2 | ||||||
MIRT652531 | TM9SF3 | transmembrane 9 superfamily member 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT653246 | SORD | sorbitol dehydrogenase | ![]() |
![]() |
2 | 2 | ||||||
MIRT658596 | EPB41L1 | erythrocyte membrane protein band 4.1 like 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT660377 | B4GALT6 | beta-1,4-galactosyltransferase 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT665758 | TMEM43 | transmembrane protein 43 | ![]() |
![]() |
2 | 2 | ||||||
MIRT666953 | PKHD1 | PKHD1, fibrocystin/polyductin | ![]() |
![]() |
2 | 2 | ||||||
MIRT667128 | NUDT3 | nudix hydrolase 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT699791 | SEC24A | SEC24 homolog A, COPII coat complex component | ![]() |
![]() |
2 | 2 | ||||||
MIRT704061 | SRCAP | Snf2 related CREBBP activator protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT714595 | HSPA4L | heat shock protein family A (Hsp70) member 4 like | ![]() |
![]() |
2 | 2 | ||||||
MIRT722695 | PCMTD1 | protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT723148 | NQO2 | N-ribosyldihydronicotinamide:quinone reductase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT731353 | FOXO1 | forkhead box O1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT735043 | SOX9 | SRY-box 9 | ![]() |
![]() |
2 | 0 | ||||||
MIRT736765 | EIF5A2 | eukaryotic translation initiation factor 5A2 | ![]() |
![]() |
![]() |
![]() |
4 | 0 | ||||
MIRT736863 | HES1 | hes family bHLH transcription factor 1 | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT737297 | EGFR | epidermal growth factor receptor | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT756214 | TOP2B | DNA topoisomerase II beta | 3 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|